Residual cardiovascular risk reduction guided by lifetime benefit estimation in patients with symptomatic atherosclerotic disease: effectiveness and cost-effectiveness.
Steven H J HagemanJannick A N DorresteijnMichiel L BotsFolkert W. AsselbergsJan WesterinkMiriam P van der MeulenArend MosterdFrank L J VisserenF W AsselbergsH M NathoeG J de BorstMichiel L BotsM I GeerlingsM H EmmelotP A de JongT LeinerA T LelyN P van der KaaijL J KappelleY M RuigrokM C VerhaarF L J VisserenJ WesterinkPublished in: European journal of preventive cardiology (2021)
Residual risk reduction guided by lifetime benefit estimation results in more CVD-free life years and more CVD events avoided compared to the conventional risk factor-based strategy. Lifetime benefit-based treatment is an effective and potentially cost-effective strategy for reducing residual CVD risk in patients with clinical manifest vascular disease.